Showing results (91-100 of 114) with videos related to
Sort By:
Pageof 12
Radiographics : a Review Publication of the Radiological Society of North America, Inc|April 25, 2024
Response Evaluation Criteria in Gastrointestinal and Abdominal Cancers: Which to Use and How to MeasureFrancesca Castagnoli, Justin Mencel, Derfel Ap Dafydd, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 18, 2026
Imaging xCT with Immuno-PET in Therapy-Resistant Non-Small Cell Lung CancerAbigail R Barber, Richard S Edwards, Sofia N Dos Santos, et al.European Journal of Nuclear Medicine and Molecular Imaging|December 25, 2019
The management impact of <sup>68</sup>gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (<sup>68</sup>Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancerMeghana Kulkarni, Simon Hughes, Andrew Mallia, et al.Journal of Thoracic Imaging|July 13, 2015
Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity AnalysisConnie Yip, Nunzia Tacelli, Martine Remy-Jardin, et al.Radiology|March 31, 2026
Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung CancerRobert O'Shea, Carolyn Horst, Thubeena Manickavasagar, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 6, 2024
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of <sup>99m</sup>Tc and <sup>188</sup>Re Theranostic Agents for Prostate CancerTruc T Pham, Ingebjørg N Hungnes, Charlotte Rivas, et al.European Radiology|February 22, 2024
Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([<sup>18</sup>F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancerDaniel Johnathan Hughes, Eleni Josephides, Robert O'Shea, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 20, 2021
A Phase II, Open-label study to assess safety and management change using <sup>68</sup>Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED studyAsim Afaq, Heather Payne, Reena Davda, et al.European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2026
Does <sup>18</sup>F-sodium fluoride PET/CT have a role in the assessment of response to <sup>223</sup>Ra therapy in men with prostatic bone metastases?Glen M Blake, Ricardo Donners, Amelia E B Moore, et al.European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2025
An explainable imaging-clinical biomarker for non-small cell lung cancer prognostication based on normalised hotspot to centroid distance and [<sup>18</sup>F]FDG PET/CT radiomicsMitchell Chen, Susan J Copley, Yidong Han, et al.Pageof 12